Joint Involvement And Aggressive Systemic Sclerosis PDF Print E-mail
Thursday, 16 September 2010 09:16
Clinical joint involvement is strikingly common in patients with systemic sclerosis (scleroderma) and is associated with a more active and severe disease phenotype, according to an analysis of the world’s largest systemic sclerosis (SSc) registry.

Synovitis proved to have a particularly strong association with systemic inflammation in this study. However, Synovitis often occurred in concert with joint contractures and/or tendon friction rubs, raising the possibility of a shared underlying mechanism in their development , Dr. Jérôme Avouac said at the annual European Congress of Rheumatology.

He presented an analysis of joint symptoms and their clinical implications in 7,286 patients with systemic sclerosis (SSc) enrolled in the EULAR Scleroderma Trials and Research (EUSTAR) registry, the world’s largest SSc database. Of registrants, 58% had the limited cutaneous subtype of SSc, 33% had the diffuse cutaneous subtype, and 9% were not classified.

Synovitis, joint contractures, and tendon friction rubs more prevalent in patients with the diffuse cutaneous subtype noted Dr. Avouac of Cochin Hospital, Paris.

Active disease, as defined by the 17-point dermal ultrasound, modified Rodnan skin scoring system, was present in 29% of the overall study population. Synovitis was associated with a highly significant 70% increased likelihood of having active disease, while tendon friction rubs were associated with a 51% increased rate. In contrast, joint contractures had no impact upon the risk of having active disease.

Synovitis was also associated with a 47% increased likelihood of having muscle weakness, a 49% increase in the risk of having elevated systolic pulmonary artery pressure, a 49% increase in the odds of having elevation of acute phase reactants, and a 29% increase in anti-topoisomerase-1 antibody positivity.

Patients with joint contractures were significantly more likely to have digital ulcerations (93% increased risk), elevated systolic pulmonary artery pressure (38% increased risk), muscle weakness (41% increase), and pulmonary fibrosis (23% increased risk), the rheumatologist continued.

Tendon friction rubs were associated with a 21% increased likelihood of experiencing digital ulceration, a 22% increase in pulmonary fibrosis, and a 38% greater likelihood of proteinuria.

These study findings provide support for making early detection of articular involvement in SSc a disease-management priority, according to Dr. Avouac.

He noted, however, that this was a cross-sectional analysis. Ongoing prospective follow-up of the EUSTAR registry participants will enable investigators to make a definitive determination of the merits of articular involvement as a predictor of disease severity

Source: Jancin, B (2010), "Joint Involvement Predicts Aggressive Systemic Sclerosis", Skin and Allergy News, viewed online at http://bit.ly/dxrK4J
 
More articles :

» TLR4 Protein Implicated In The Fibrosis Associated With Scleroderma

An international multi-disciplinary research team led by scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.Recently reported in the , this finding has implications for...

» What You Should Know About The AntiNuclear Antibody Or ANA Test

How is it used?The ANA test is ordered to help screen for autoimmune disorders and is most often used as one of the tests to diagnose (SLE). Depending on the patient's symptoms and the suspected diagnosis, ANA may be ordered along with one or more...

» L-selectin and Skin Damage in Systemic Sclerosis

L-selectin ligands are induced on the endothelium of inflammatory sites. L-selectin expression on neutrophils and monocytes may mediate the primary adhesion of these cells at sites of inflammation by mediating the leukocyte-leukocyte interactions...

» A Checklist For Scleroderma Patients

The has published a quite useful checklist of items, which has been found useful to patients. They have noted that the list is by no means comprehensive, but is intended as a guideline to assist Scleroderma patients, and was developed by patients...

» Report on the 2010 Systemic Sclerosis World Congress

Robert J. Riggs, CEO of the recently reported on his experience at the recently concluded , held in Florence, Italy. Here's a brief excerpt. In February, I attended the 1st World Congress on Systemic Sclerosis in Florence, Italy. The three-day...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh